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path arrays, may have a superior resolu-
tion and may evolve to important
alternatives to FISH. Genome-wide,
high-resolution analyses—as applied
here—yield additional information as
compared to region-specific approaches
and have therefore the potential to
identify additional genomic regions of
prognostic relevance. This case demon-
strates that all molecular genetic results
should be considered critically under
the light of the clinical picture.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We thank Peter Lichter, Bernhard Radlwimmer, and
Grischa Toedt from the Deutsches Krebsforschungs-
zentrum, Heidelberg, Germany, for providing BAC
microarrays and Ruthild Weber, Institute of Human
Genetics, University of Bonn, Germany, for provid-
ing the BAC clone. This study was supported by the
Jubilaeumsfonds of the Oesterreichische National-
bank Grant No. 12480. Anna C. Obenauf is funded
by the PhD-Program Molecular Medicine of the
Medical University of Graz.
Thomas Wiesner1, Anna C. Obenauf 2,
Jochen B. Geigl2, Eva-Maria Vallant2,
Michael R. Speicher2, Regina
Fink-Puches1, Helmut Kerl1 and
Lorenzo Cerroni1
1Department of Dermatology, Medical
University of Graz, Graz, Austria and 2Institute
of Human Genetics, Medical University of
Graz, Graz, Austria
E-mail: lorenzo.cerroni@meduni-graz.at
REFERENCES
Cerroni L, Gatter H, Kerl H (2005) Large B-cell
lymphoma, leg type. In: An illustrated Guide
to Skin Lymphoma. (Cerroni L, Gatter K, Kerl
H, eds), Oxford: Blackwell Publishing, 112–6
Dijkman R, Tensen CP, Jordanova ES, Knijnenburg J,
Hoefnagel JJ, Mulder AA et al. (2006) Array-
based comparative genomic hybridization
analysis reveals recurrent chromosomal al-
terations and prognostic parameters in pri-
mary cutaneous large B-cell lymphoma.
J Clin Oncol 24:296–305
Grange F, Beylot-Barry M, Courville P, Maubec E,
Bagot M, Vergier B et al. (2007) Primary
cutaneous diffuse large B-cell lymphoma, leg
type. clinicopathologic features and prognos-
tic analysis in 60 cases. Arch Dermatol
143:1144–50
Kodama K, Massone C, Chott A, Metze D, Kerl H,
Cerroni L (2005) Primary cutaneous large
B-cell lymphomas: clinicopathologic fea-
tures, classification, and prognostic factors
in a large series of patients. Blood
106:2491–7
Senff NJ, Zoutman WH, Vermeer MH, Van der
Velden PA, Willemze R, Tensen CP (2007)
Fine-mapping chromosomal loss at 9p21:
correlation with prognosis in primary cuta-
neous large B-cell lymphoma leg type.
J Invest Dermatol 127:S92
Wiesner T, Streubel B, Huber D, Kerl H, Chott A,
Cerroni L (2005) Genetic aberrations in
primary cutaneous large B-cell lymphoma:
a fluorescence in situ hybridization study of
25 cases. Am J Surg Pathol 29:666–73
Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E,
Swerdlow SH et al. (2005) WHO-EORTC
classification for cutaneous lymphomas.
Blood 105:3768–75
Zielinski B, Gratias S, Toedt G, Mendrzyk F,
Stange DE, Radlwimmer B et al. (2005)
Detection of chromosomal imbalances in
retinoblastoma by matrix-based comparative
genomic hybridization. Genes Chromosomes
Cancer 43:294–301
IL-31 Receptor Alpha Expression in Epidermal
Keratinocytes Is Modulated by Cell Differentiation
and Interferon Gamma
Journal of Investigative Dermatology (2009) 129, 240–243; doi:10.1038/jid.2008.183; published online 26 June 2008
TO THE EDITOR
Recently, IL-31 has been identified as a
short-chain 4-helix bundle cytokine that
is expressed by activated CD4þ T cells,
preferentially by T cells skewed toward
a T helper type 2 TH2-type pheno-
type (Dillon et al., 2004). IL-31 signals
through a heteromeric receptor complex
composed of the IL-31 receptor alpha
(IL-31Ra) and the oncostatin M receptor
beta (Dillon et al., 2004). The IL-31Ra
was originally identified as gp130-like
monocyte receptor (Ghilardi et al.,
2002) and gp130-like receptor (Diveu
et al., 2003, Dreuw et al., 2004) and
shows 28% homology to gp130, the
common signaling receptor subunit of
the family of IL-6-type cytokines.
Expressions of IL-31Ra and oncosta-
tin M receptor beta mRNA have been
shown to be induced in activated
monocytes, whereas tissues of the skin,
testis, thymus, and trachea, as well as
intestinal epithelial cells and dorsal
root ganglia express mRNA for both
receptors constitutively (Dillon et al.,
2004; Bando et al., 2006; Sonkoly
et al., 2006; Dambacher et al., 2007).
Engagement of the receptor complex
resulted in activation of Jak1, and to a
minor extent of Jak2, as well as STAT1,
STAT3, STAT5, and MAPK and PI3K
signaling pathways in glioblastoma and
melanoma tumor cells and lung epithe-
lial cells (Diveu et al., 2004; Chatto-
padhyay et al., 2007, Dambacher et al.,
2007).
So far, biological functions of this
previously unknown cytokine were
mainly analyzed in skin diseases such
as atopic dermatitis (AD) or allergic
contact dermatitis, in which increased
expression rates of IL-31 were detected
(Neis et al., 2006, Bilsborough et al.,
2006, Sonkoly et al., 2006). In vivo,
Staphylococcal superantigen strongly
induced IL-31 expression in PBMCs
obtained from patients with AD (Sonkoly
et al., 2006). In psoriatic plaques, ex-
pression of IL-31 was absent, confirming
an involvement of IL-31 in TH2-
Abbreviations: AD, atopic dermatitis; IL-31Ra, IL-31 receptor alpha; NHEK, normal human epidermal
keratinocyte; TH2, T helper type 2
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mediated skin diseases. Likewise, in
NC/Nga mice, an experimental animal
model for AD, a good correlation
between the scratching counts and
expression of IL-31 mRNA was demon-
strated (Takaoka et al., 2005, 2006), and
transgenic mice overexpressing IL-31
develop a skin disorder characterized
by severe pruritus, alopecia, and skin
lesions (Dillon et al., 2004).
Although an enhanced expression of
IL-31Ra has been described in inflam-
matory skin diseases, the influence of
cell differentiation on the expression of
the IL-31Ra in skin cells was largely
unknown. We therefore analyzed the
effects of the cellular differentiation
state on epidermal mRNA and protein
levels of IL-31Ra under culture condi-
tions when epidermal cultures exhibit
predominantly basal, spinous, and
granular cell phenotypes (Du et al.,
2006). NHEKs were obtained from fore-
skin specimen by dispase separation
(BD Biosciences) of the epidemal sheet
from the dermis and subsequent trypsin
digestion (Cambrex, Walkersville, MD)
of the epidermis (Baron et al., 2005). All
studies were approved by the ethical
committee of the University Hospital,
RWTH, Aachen. Participants gave their
written informed consent, and the
study was conducted according to
the Declaration of Helsinki Principles.
The differentiated keratinocyte pheno-
type was defined by cellular morpho-
logy and expression of differentiation-
specific gene markers. Cytokeratin 10
mRNA (KRT 10) expression, a specific
marker of the basal to spinous transition
in vivo, was upregulated during the first
week of in vitro differentiation, achiev-
ing maximal levels at days 5 and 10
(Figure 1a). The upregulation of loricrin
mRNA, a specific marker of the spinous
to granular transition in vivo, required
2 weeks of cultivation of keratinocytes
in differentiation medium (1.4 mM Ca2þ )
(Figure 1b). Interestingly, IL-31RamRNA
completely disappeared during the
process of differentiation. Already at
the transition from basal to spinous
phenotype (d5), hardly any mRNA was
detectable by quantitative reverse trans-
cription-PCR (Figure 1c). Expression of
oncostatin M receptor beta mRNA was
decreased on day 5 but not significantly
altered during the late phases of kerati-
nocyte differentiation (Figure 1d). Using
an IL-31Ra-specific antibody (R&D
Systems, Wiesbaden-Nordenstadt), we
confirmed a strong downregulation of
the receptor at the protein level when
differentiation of normal human epider-
mal keratinocytes (NHEK) was induced
by culturing the cells in differentiation
medium containing 1.4 mM Ca2þ for
more than 3 days (Figure 2a). Protein
expression was not traceable in terminal
differentiated keratinocytes (day 15)
resembling granular cell phenotype.
Additionally, we did not find IL-31Ra
expression in dermal fibroblasts (Figure
2a, lane 8), which is in agreement
with the findings by Chattopadhyay
et al. (2007) that fibroblastic cells
did not respond to IL-31 treatment
(Chattopadhyay et al., 2007). Monocytes
induced with 1000 U ml1 IFN-g for
48 h revealed a strong upregulation of
IL-31Ra expression (Figure 2a, lane 7)
(Dillon et al., 2004). Stimulation of
proliferating NHEK with IFN-g led to
an upregulation of IL-31Ra mRNA
(Figure 1e) and protein expression
(Figure 2b, lane 4). Stimulation of
NHEK in early phases of differentiation
(d6, d8; Figure 1f) with IFN-g also
revealed an upregulation of IL-31Ra
expression. In the late phases of differ-
entiation (d12, d15, data not shown),
IFN-g treatment of NHEK had no effect
of IL-31Ra expression. In inflamed skin,
keratinocytes in the early stages of
differentiation might therefore be more
responsive to IL-31. Challenge with
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Figure 1. mRNA expression of IL-31 Ra decreases in differentiated normal human epidermal
keratinocytes (NHEK) and is upregulated after stimulation with IFNc. TaqMan real-time PCR analysis
of NHEK cultured in differentiation medium containing 1.4 mM Ca2þ : upregulation of (a) cytokeratin
10 (KRT 10) and (b) loricrin (LOR) mRNA expression serves as marker for the induced differentiation
process. (c) Expression of IL-31Ra mRNA was 29-fold reduced in differentiated keratinocytes (day 15)
compared with proliferating keratinocytes (d 0). (d) Expression of oncostatin M receptor beta mRNA
was decreased on days 1 and 5 but not significantly altered during the late phases of keratinocyte
differentiation. The relative mRNA levels were normalized to 18S rRNA. (e) Expression of IL-31Ra mRNA
was fivefold induced in proliferating NHEK 24 h after stimulation with 20 ng ml1 INF-g. Incubation of
NHEK with 10 ng ml1 IL-1a, 10 ng ml1 TNF-a and a cocktail containing 10 ng ml1 IL-1a, 5 ng ml1
TNF-a, and 5 ng ml1 IL-6 for 24 h did not alter IL-31Ra mRNA expression. (f) Twenty four hours after
stimulation with 20 ng ml1 INF-g, expression of IL-31Ra mRNA was 3.8-fold induced in differentiated
NHEK (cultured in medium containing 1.4 mM Ca2þ for 8 days). Incubation of NHEK with 10 ng ml1
IL-1a, 10 ng ml1 TNF-a, and a cocktail containing 10 ng ml1 IL-1a, 5 ng ml1 TNF-a, and 5 ng ml1
IL-6 for 24 h did not alter IL-31Ra mRNA expression.
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IL-1a, tumor necrosis factor-a (TNF-a)
and a mixture of pro-inflammatory
cytokines (TNF-a, IL-1a, and IL-6;
Tjabringa et al., 2007) did not alter
IL-31Ra expression in proliferating or
differentiated NHEK (Figure 1e and f,
2b, lane 5).
Loss of receptor expression in late-
stage keratinocytes consequently led
to a loss of cytokine responsiveness;
although proliferating keratinocytes
respond to IL-31 treatment with in-
creased tyrosine phosphorylation of
STAT3, we could not detect any STAT
activation in differentiated keratinocytes
(Figure 2c). In contrast, stimulation
with OSM resulted in STAT3 tyrosine
phosphorylation irrespective of the dif-
ferentiation state, which indicates that
differentiated keratinocytes are not un-
responsive to cytokine treatment, in
general (Figure 2c).
Primary keratinocytes are known to
express both IL-31 receptor compo-
nents and respond to IL-31 stimulation
with the production of chemo-
kines such as thymus and activation-
regulated chemokine (TARC/CCL17)
or macrophage-derived chemokine
(MDC/CCL22; Dillon et al., 2004).
Using immunohistology, Bilsborough
et al. (2006) have demonstrated that
levels of IL-31Ra expressed on kerati-
nocytes from AD skin biopsy specimens
were consistently higher than the levels
observed in skin biopsy specimen from
healthy control subjects. These data
correspond to our findings, as prolifer-
ating keratinocytes show higher levels
of IL-31Ra and remain sensitive to IL-31
stimulation, whereas differentiated cells
become unresponsive (Figure 1c, 2a
and c).
Recently, a prominent involvement
of activated Th1-subset of T-cells and
increased expression of receptor of
IFN-g on keratinocytes has been detec-
ted in acute skin lesions of AD (Lugovic´
et al., 2005). In our studies, INF-g had a
strong stimulatory influence on the
expression of IL-31Ra in proliferat-
ing NEHK (Figure 1e, 2b). Additional
GeneChip Human Exon 1.0 ST array
analysis of proliferating and differen-
tiated NHEK (data not shown) revealed
a downregulation of IFN-g receptor 2
in differentiated keratinocytes, which
may correlate with the downregulation
of the IL-31Ra detected in these cells
(Figure 1c, 2a).
Broxmeyer et al. (2007) demons-
trated a survival-enhancing effect of
IL-31 on murine hematogenic progeni-
tor cells in vitro but no modulation of
proliferation. So far, IL-31 has been
shown to have a strong growth inhibi-
tory activity on epithelial cells
(Chattopadhyay et al., 2007, Damba-
cher et al., 2007). Chattopadhyay et al.
(2007) delineated that IL-31 was
highly effective in suppressing prolif-
eration by altering expression of cell-
cycle proteins, including upregulation
of p27Kip1 and downregulation of cyclin
B1, CDC2, CDK2, MCM4, and the
retinoblastoma protein. Therefore, cells
seem to be arrested in G0 phase with-
out induction of apoptosis. Whether IL-
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Figure 2. Influence of cell differentiation and inflammatory cytokines on IL-31 Ra protein expression
and IL-31 Ra dependent signaling pathways. Western blot analysis of IL-31Ra expression in NHEK (a) at
different stages of cell differentiation, (b) after stimulation with pro-inflammatory cytokines. (c) Analysis
of signaling pathways in nondifferentiated (d 0) and differentiated (d 15) NHEK in response to oncostatin
M and IL-31. (a) For Western blot analysis, NHEK were cultured in differentiation medium containing
1.4 mM Ca2þ . Cells were harvested at the times indicated and total cell lysates were prepared and
separated by SDS-PAGE. ¼ histological features of NHEK at day 0 or 15. Dermal fibroblasts (NHDF)
and monocytes (MØ) stimulated with 1000 U ml1 IFN-g for 48 h were used as negative or positive
controls. (b) Proliferating NHEK were incubated with 10 ng ml1 IL-1a, 10 ng ml1 TNF-a, 20 ng ml1
INF-g, and a cocktail containing 10 ng ml1 IL-1a, 5 ng ml1 TNF-a and 5 ng ml1 IL-6 for 48 h. Western
blots were developed with an antibody against IL-31Ra. Blots were stripped and reprobed with a primary
monoclonal anti-human b-actin antibody. (c) NHEK at day 0 or cultured in differentiation medium
containing 1.4 mM Ca2þ for 15 days were stimulated with 20 ng ml1 OSM or 100 ng ml1 IL-31 for the
indicated time points. Total cell lysates were separated by SDS-PAGE. Western blots were developed
with antisera specific for the indicated proteins.
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31 might be involved in the molecular
switch from proliferation to differentia-
tion needs to be determined.
In conclusion, in vitro studies ana-
lyzing the effects of the previously
unknown cytokine IL-31 on epidermal
keratinocytes should consider the
variation of IL-31Ra expression, which
depends on the status of cellular differ-
entiation and the influence of pro-
inflammatory cytokines. Further clinical
studies and highly specific mAbs are
necessary to assess the impact of these
findings in vivo.
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TO THE EDITOR
Imiquimod, an imidazoquinoline im-
mune response modifier, has been ap-
proved for the topical treatment of
anogenital warts and has shown efficacy
in superficial basal cell carcinomas and
actinic keratoses (Beutner et al., 1999;
Ulrich et al., 2006). When applied
topically, it induces strong T-lymphocy-
tic infiltrates due to its binding to Toll-
like receptor 7 (TLR7) and stimulation of
various cytokines (Hemmi et al., 2002).
It has the ability to enhance both the
innate and cellular immune responses by
acting on a number of cell types (Sauder
2000; Dahl 2002).
The development of vitiligo-like
hypopigmentary lesions associated with
topical imiquimod has been reported
(Brown et al., 2005; Stefanaki et al.,
2006). Taking into consideration those
actions, imiquimod may have acted as a
triggering factor in an individual suscep-
tible to the development of vitiligo. If
Abbreviations: G3PDH, glyceraldehyde-3-phosphate dehydrogenase; MITF, microphthalmia-associated
transcription factor; siRNA, small interfering RNA; TLR, Toll-like receptor
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